References
Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2010; 90: 202–3.
Kim EH, Kim DM, Lee JY. Perifollicular xanthoma occurring in patients after erlotinib treatment. Dermatol Ther (Heidelb) 2022; 12: 1281–6.
Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 2016; 46: 291–8.
Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol 1979; 73: 108–11.
Nazzaro-Porro M, Passi S, Boniforti L, Belsito F. Effects of aging on fatty acids in skin surface lipids. J Invest Dermatol 1979; 73: 112–7.
Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13: 120–3.
Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994; 130: 748–52.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest: none.
Additional information
Financial support: none.
About this article
Cite this article
Yamada, M., Kokubu, H. & Fujimoto, N. Perifollicular xanthoma occurring after treatment with osimertinib. Eur J Dermatol 33, 562–564 (2023). https://doi.org/10.1684/ejd.2023.4547
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2023.4547